FDA Rejects China's Pioneering Lung Cancer Drug
Key Points:
- The FDA has declined to approve ivonescimab, a cancer drug held by Summit Therapeutics, for certain advanced lung cancer patients after a global trial failed to demonstrate improved overall survival compared to chemotherapy alone.
- Although ivonescimab slowed disease progression, the FDA was unconvinced by Summit's additional analyses suggesting a survival benefit, citing slow trial enrollment as a potential factor.
- Ivonescimab targets two proteins involved in immune evasion and tumor blood supply and had shown promise in a 2024 Chinese trial, outperforming Merck's Keytruda, but US regulators require confirmation in Western populations.
- A larger ongoing trial comparing ivonescimab directly with Keytruda in frontline lung cancer patients is expected to report results this year, which could lead Summit to resubmit for FDA approval.
- Beyond lung cancer, ivonescimab is also being tested for efficacy against breast, colon, and bladder cancers.